- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07742826
Comparison of PRF and Corticosteroids in Impacted Third Molar Surgery
July 29, 2026 updated by: Meliz Kneebone, Final International University
Comparison of Postoperative Effects of PRF and Corticosteroid Treatments in Impacted Third Molar Surgery
This prospective, randomized interventional study aims to compare the postoperative effects of standard treatment (control), platelet-rich fibrin (PRF), and PRF combined with corticosteroid treatment in patients undergoing impacted mandibular third molar surgery.
A total of 60 participants will be randomly assigned to one of three treatment groups according to the study protocol.
Postoperative pain, facial swelling, and trismus will be evaluated on postoperative days 1, 2, 3, and 7.
The findings of this study are expected to provide evidence regarding the effectiveness of PRF alone and PRF combined with corticosteroid treatment in reducing postoperative complications following impacted mandibular third molar surgery.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Meliz Kneebone, DDS
- Phone Number: +905338425731
- Email: meliz-95@hotmail.com
Study Locations
-
-
-
Nicosia, Cyprus, 2323
- Recruiting
- Final International University Faculty of Dentistry
-
Contact:
- Meliz Kneebone, DDS
- Phone Number: +905338425731
- Email: meliz-95@hotmail.com
-
Principal Investigator:
- Meliz Kneebone, DDS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Patients aged 18 years and older.
- Patients with good general health
- Patients with complete clinical and radiographic examination (panoramic radiograph/CBCT if applicable)
- Patients willing and able to attend all postoperative follow-up visits
Exclusion Criteria:
- Patients with systemic diseases that may impair wound healing (e.g., uncontrolled diabetes, immunodeficiency).
- Pregnant or breastfeeding women.
- Patients with acute infection, abscess, or pericoronitis at the surgical site.
- Patients with a history of allergy or contraindication to corticosteroids, local anesthetics, or prescribed medications.
- Patients using corticosteroids, anticoagulants, immunosuppressive drugs, or bisphosphonates.
- Patients with bleeding disorders.
- Patients with previous radiotherapy to the head and neck region.
- Patients unable or unwilling to comply with the study protocol or attend follow-up visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard Postoperative Treatment (Control)
Participants receive standard postoperative treatment following impacted mandibular third molar surgery, including amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash.
No platelet-rich fibrin (PRF) or corticosteroid is administered.
|
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
|
|
Experimental: Platelet-Rich Fibrin (PRF)
Participants receive platelet-rich fibrin (PRF) placed into the extraction socket in addition to standard postoperative treatment consisting of amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash following impacted mandibular third molar surgery.
|
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
Autologous platelet-rich fibrin (PRF) prepared from the participant's venous blood by centrifugation at 3000 rpm for 10 minutes, and then placed into the extraction socket immediately after impacted mandibular third molar surgery.
|
|
Experimental: Platelet-Rich Fibrin Plus Corticosteroid
Participants receive platelet-rich fibrin (PRF) placement into the extraction socket followed by intramuscular corticosteroid administration, in addition to standard postoperative treatment consisting of amoxicillin/clavulanic acid (Augmentin), paracetamol, and chlorhexidine mouthwash following impacted mandibular third molar surgery.
|
Amoxicillin/clavulanic acid administered postoperatively according to the study protocol.
Paracetamol 500 mg tablets administered postoperatively for pain control according to the study protocol.
Chlorhexidine mouthwash administered postoperatively according to the study protocol.
Autologous platelet-rich fibrin (PRF) prepared from the participant's venous blood by centrifugation at 3000 rpm for 10 minutes, and then placed into the extraction socket immediately after impacted mandibular third molar surgery.
Dexamethasone (8 mg/2 mL) administered as a single intramuscular injection immediately after impacted mandibular third molar surgery in addition to platelet-rich fibrin (PRF), according to the study protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative Pain
Time Frame: Postoperative Days 1, 2, 3, and 7
|
Postoperative pain assessed using a 10-cm Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable.
|
Postoperative Days 1, 2, 3, and 7
|
|
Postoperative Swelling
Time Frame: Postoperative Days 1, 2, 3, and 7
|
Postoperative facial swelling assessed using a flexible measuring tape by recording the linear distances from the tragus to the pogonion (chin point), the tragus to the corner of the mouth, and the lateral canthus of the eye to the angle of the mandible.
|
Postoperative Days 1, 2, 3, and 7
|
|
Trismus
Time Frame: Postoperative Days 1, 2, 3, and 7
|
Trismus assessed by measuring the maximum interincisal mouth opening (mm) using a digital caliper.
|
Postoperative Days 1, 2, 3, and 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Donmezer CM, Bilginaylar K. Comparison of the Postoperative Effects of Local Antibiotic versus Systemic Antibiotic with the Use of Platelet-Rich Fibrin on Impacted Mandibular Third Molar Surgery: A Randomized Split-Mouth Study. Biomed Res Int. 2021 Dec 2;2021:3040661. doi: 10.1155/2021/3040661. eCollection 2021.
- Koc O, Er N, Karaca C, Bilginaylar K. Comparison of the effects of submucosal hyaluronidase and dexamethasone on postoperative edema, pain, trismus, and infection following impacted third molar surgery. BMC Oral Health. 2024 Aug 30;24(1):1018. doi: 10.1186/s12903-024-04729-1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 3, 2024
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
August 1, 2026
Study Registration Dates
First Submitted
July 28, 2026
First Submitted That Met QC Criteria
July 29, 2026
First Posted (Actual)
August 3, 2026
Study Record Updates
Last Update Posted (Actual)
August 3, 2026
Last Update Submitted That Met QC Criteria
July 29, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Nervous System Diseases
- Neuromuscular Manifestations
- Pathologic Processes
- Spasm
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain, Postoperative
- Trismus
- Postoperative Complications
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Pharmaceutical Preparations
- Polycyclic Compounds
- Anilides
- Amides
- Aniline Compounds
- Amines
- Acetanilides
- Pregnadienes
- Pregnanes
- Steroids
- Fused-Ring Compounds
- Steroids, Fluorinated
- Pregnadienetriols
- Biguanides
- Guanidines
- Amidines
- Drug Combinations
- Penicillin G
- beta-Lactams
- Lactams
- Clavulanic Acid
- Clavulanic Acids
- Ampicillin
- Penicillins
- Amoxicillin
- Dexamethasone
- Acetaminophen
- Chlorhexidine
- Amoxicillin-Potassium Clavulanate Combination
Other Study ID Numbers
- Final International University
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data will not be shared because the study was conducted as part of an academic thesis, and there is no institutional plan for sharing de-identified participant-level data.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.